Program
Tacrolimus
Also written as “tacrolimus”, “Advagraf” and “tacrolimus ointment”.
Its studies are mostly in Dermatitis, Atopic · Renal Insufficiency · Arthritis, Rheumatoid · Graft vs Host Disease · Lupus Nephritis, led by 17 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 1120 open or running | phase 4since Mar 23, 2005 | May 8, 2002 | none ahead |
| Novartis | 140 open or running | phase 4since Sep 27, 2005 | Sep 27, 2005 | none ahead |
| Veloxis Pharmaceuticals | 110 open or running | phase 3since Dec 19, 2008 | Jul 2, 2007 | none ahead |
| Pfizer | 60 open or running | phase 4since Sep 12, 2005 | Jun 30, 2004 | none ahead |
| Johnson & Johnson | 50 open or running | phase 4since Feb 24, 2006 | Feb 24, 2006 | none ahead |
| Panacea Biotec | 40 open or running | no phasesince Mar 2, 2010 | Mar 2, 2010 | none ahead |
| Chiesi Farmaceutici | 30 open or running | phase 4since Apr 29, 2015 | Apr 29, 2015 | none ahead |
| Chong Kun Dang Pharmaceutical | 30 open or running | phase 4since Dec 4, 2012 | Dec 4, 2012 | none ahead |
| Hoffmann-La Roche | 30 open or running | phase 4since Jun 30, 2005 | Jun 30, 2005 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since May 26, 2010 | May 26, 2010 | none ahead |
| linical-korea | 20 open or running | phase 4since Feb 17, 2021 | Feb 17, 2021 | none ahead |
| lipella-pharmaceuticals-inc | 21 open or running | phase 2since Apr 17, 2017 | Apr 17, 2017 | none ahead |
| glenmark-pharmaceuticals-ltd-india | 10 open or running | phase 3since Nov 9, 2015 | Nov 9, 2015 | none ahead |
| novaliq-gmbh | 11 open or running | phase 2since Dec 9, 2025 | Dec 9, 2025 | Dec 2026phase 2 · NCT07285070 |
| Sun Pharmaceutical Industries | 10 open or running | phase 1since Jan 28, 2009 | Jan 28, 2009 | none ahead |
| tff-pharmaceuticals-inc | 10 open or running | phase 2since Aug 11, 2022 | Aug 11, 2022 | none ahead |
| VIVUS | 11 open or running | phase 3since May 18, 2026 | May 18, 2026 | May 31, 2028phase 3 · NCT07612657 |
Also a collaborator on its studies: Kyowa Kirin, novotech-australia-pty-limited, parexel, achillion-a-wholly-owned-subsidiary-of-alexion, cromsource, bio-kinetic-europe-ltd, ppd-development-lp, aptuit, astellas-pharma-us-inc and basilea-pharmaceutica-international-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Mar 16, 2011.
- Oct 28, 2016Phase 2 study in Kidney TransplantationChiesi Farmaceutici · NCT02970630 · 28 enrolled · Italy
- Apr 17, 2017lipella-pharmaceuticals-inc's first study: phase 2 study in Cystitis, HemorrhagicNew to lipella-pharmaceuticals-inclipella-pharmaceuticals-inc · NCT03129126 · 13 enrolled · United States
- Feb 21, 2018Phase 4 study in Kidney TransplantationAstellas Pharma · NCT03465969 · 80 enrolled · France, United Kingdom
- Aug 22, 2018Phase 4 study in Kidney TransplantAstellas Pharma · NCT03644485 · 284 enrolled · China
- Nov 8, 2018Phase 4 study in Arthritis, RheumatoidAstellas Pharma · NCT03737708 · 21 enrolled · Korea, Republic of
- Jan 3, 2019Phase 4 study in Kidney TransplantChong Kun Dang Pharmaceutical · NCT03794492 · 169 enrolled · Korea, Republic of
- Jun 5, 2019Phase 1 study in Kidney TransplantNovartis · NCT03978494 · France, Germany
- Aug 28, 2019Phase 4 study in Kidney TransplantChong Kun Dang Pharmaceutical · NCT04102943 · 128 enrolled · South Korea
- Feb 17, 2021linical-korea's first studies: 2 phase 4 studiesNew to linical-korealinical-korea · NCT04763096, NCT04761731
- Nov 29, 20212 phase 4 studies in Liver TransplantationAstellas Pharma · NCT05152628, NCT05153915
- Aug 11, 2022tff-pharmaceuticals-inc's first study: phase 2 study in Lung Transplant RejectionNew to tff-pharmaceuticals-inctff-pharmaceuticals-inc · NCT05501574 · 14 enrolled · Australia
- Dec 19, 2023Phase 2 study in Lichen Planus, Orallipella-pharmaceuticals-inc · NCT06233591 · 24 enrolled · United States
- Dec 9, 2025novaliq-gmbh's first study: phase 2 study in Non-infectious Anterior UveitisNew to novaliq-gmbhnovaliq-gmbh · NCT07285070 · 20 enrolled · United States
- May 18, 2026VIVUS's first study: phase 3 study in Pulmonary Arterial HypertensionNew to VIVUSVIVUS · NCT07612657 · 300 planned
Ahead
- Dec 2026Primary completion: phase 2 study in Non-infectious Anterior Uveitisnovaliq-gmbh · NCT07285070
- May 31, 2028Primary completion: phase 3 study in Pulmonary Arterial HypertensionVIVUS · NCT07612657
TargetBeta
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule
Other programs on FKBP1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Everolimusrule | Novartis | phase 4 | 131 |
Studies
The newest 60 of 172 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07612657Pulmonary Arterial Hypertension | 3 | Not yet recruiting | VIVUS | May 31, 2028 | 300 |
| NCT07285070Non-infectious Anterior Uveitis · United States | 2 | Active, not recruiting | novaliq-gmbh | Dec 2026 | 20 |
| NCT06233591Lichen Planus, Oral · United States | 2 | Active, not recruiting | lipella-pharmaceuticals-inc | Jun 1, 2025 | 24 |
| NCT05501574Lung Transplant Rejection · Australia | 2 | Terminated | tff-pharmaceuticals-inc | Oct 29, 2024 | 14 |
| NCT05153915Liver Transplantation · China | 4 | Completed | Astellas Pharma | Mar 14, 2024 | 56 |
| NCT05152628Liver Transplantation · China | 4 | Completed | Astellas Pharma | Mar 6, 2024 | 55 |
| NCT04763096Evidence of Liver Transplantation · Korea, Republic of | 4 | Completed | linical-korea | Apr 2020 | 101 |
| NCT04761731Liver Transplantation | 4 | Completed | linical-korea | Dec 14, 2017 | 31 |
| NCT04102943Kidney Transplant · South Korea | 4 | Completed | Chong Kun Dang Pharmaceutical | Sep 29, 2020 | 128 |
| NCT03978494Kidney Transplant · France, Germany | 1 | Withdrawn | Novartis | May 3, 2020 | 0 |
| NCT03794492Kidney Transplant · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | Jul 22, 2022 | 169 |
| NCT03737708Arthritis, Rheumatoid · Korea, Republic of | 4 | Completed | Astellas Pharma | Jun 16, 2020 | 21 |
| NCT03644485Kidney Transplant · China | 4 | Completed | Astellas Pharma | Jul 15, 2022 | 284 |
| NCT03465969Kidney Transplantation · France, United Kingdom | 4 | Completed | Astellas Pharma | Sep 14, 2018 | 80 |
| NCT03129126Cystitis, Hemorrhagic · United States | 2 | Completed | lipella-pharmaceuticals-inc | Aug 21, 2023 | 13 |
| NCT02970630Kidney Transplantation · Italy | 2 | Completed | Chiesi Farmaceutici | Feb 22, 2018 | 28 |
| NCT02963103Kidney Transplantation · Korea, Republic of | 4 | Terminated | Astellas Pharma | Oct 2012 | 13 |
| NCT02706678Renal Transplant Recipients · China | 4 | Completed | Astellas Pharma | Aug 1, 2012 | 105 |
| NCT02723591Kidney Transplantation · United States | 4 | Completed | Astellas Pharma | Jun 14, 2019 | 599 |
| NCT02660684Graft vs Host Disease · Korea, Republic of | 4 | Completed | Astellas Pharma | Feb 2010 | 39 |
| NCT02601703Dermatitis, Atopic · United States | 3 | Completed | glenmark-pharmaceuticals-ltd-india | Oct 2016 | 1,110 |
| NCT02563782Macular Degeneration · United States | 2 | Withdrawn | Astellas Pharma | May 5, 2017 | 0 |
| NCT02500212Organ or Tissue Transplant; Complications · France | 4 | Completed | Chiesi Farmaceutici | Jun 2016 | 75 |
| NCT02457221Lupus Nephritis · China | 3 | Completed | Astellas Pharma | Sep 10, 2018 | 314 |
| NCT02432833Kidney Failure, Chronic · Italy | 4 | Completed | Chiesi Farmaceutici | Jan 24, 2017 | 428 |
| NCT02432053Kidney Transplantation · India | 4 | Completed | Astellas Pharma | May 2013 | 92 |
| NCT02339246Renal Insufficiency · United States | 3 | Completed | Veloxis Pharmaceuticals | Mar 2015 | 32 |
| NCT02268201Kidney Transplant Recipients · China | 4 | Terminated | Astellas Pharma | Mar 31, 2015 | 17 |
| NCT02217410Kidney Transplantation · United States, Brazil, Germany and more | 2 | Completed | Novartis | Nov 29, 2017 | 59 |
| NCT02161237Kidney Transplantation · Korea, Republic of, Taiwan | 4 | Completed | Astellas Pharma | Dec 22, 2016 | 73 |
| NCT02118896Heart Transplantation · United States, Australia, Austria and more | 3 | Completed | Astellas Pharma | Oct 7, 2009 | 850 |
| NCT02115113Liver Transplantation · Italy | 3 | Completed | Novartis | Sep 30, 2016 | 78 |
| NCT02034747Kidney Transplant · South Korea | 4 | Completed | Astellas Pharma | Nov 7, 2015 | 150 |
| NCT01962922Renal Insufficiency · United States | 3 | Completed | Veloxis Pharmaceuticals | Jul 2015 | 50 |
| NCT01882322de Novo Liver Transplant Subjects · Korea, Republic of | 4 | Completed | Astellas Pharma | Jan 3, 2017 | 36 |
| NCT01839929Kidney Transplantation · Korea, Republic of | 4 | Completed | Astellas Pharma | Feb 2013 | 138 |
| NCT01843348Rejection, Psychology · France, Germany | 3 | Completed | Novartis | Mar 23, 2016 | 612 |
| NCT01828879Dermatitis, Atopic · Vietnam | 4 | Completed | Johnson & Johnson | Jun 2009 | 74 |
| NCT01782729Dermatitis, Atopic · Vietnam | 4 | Completed | Johnson & Johnson | Nov 2008 | 30 |
| NCT01780844Kidney Transplantation · United States | 2 | Completed | Astellas Pharma | Jun 30, 2014 | 149 |
| NCT01763580Nephrosis, Lipoid · Korea, Republic of | 4 | Completed | Astellas Pharma | May 2, 2017 | 144 |
| NCT01745159Lymphoma, Follicular · China | 4 | Completed | Astellas Pharma | Nov 2013 | 125 |
| NCT01746680Arthritis, Rheumatoid · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | Jun 2015 | 111 |
| NCT01742676Renal Transplantation · Korea, Republic of | 4 | Completed | Astellas Pharma | Apr 2013 | 100 |
| NCT01742624de Novo Kidney Transplantation · Korea, Republic of | 4 | Completed | Astellas Pharma | Jun 2012 | 60 |
| NCT01681134Healthy · Canada | 1 | Completed | Astellas Pharma | Oct 2012 | 19 |
| NCT01666951Renal Insufficiency · United States | 2 | Completed | Veloxis Pharmaceuticals | Mar 2013 | 36 |
| NCT01649427Graft vs Host Disease · Germany | 4 | Completed | Novartis | Aug 20, 2015 | 73 |
| NCT01614665Heart Transplantation · Czechia, France, Italy and more | 2 | Completed | Astellas Pharma | Apr 21, 2021 | 44 |
| NCT01535547Pharmacokinetics of Isavuconazole · United States | 1 | Completed | Astellas Pharma | Jan 2012 | 24 |
| NCT01511003Arthritis, Rheumatoid · Korea, Republic of | 4 | Completed | Astellas Pharma | May 11, 2015 | 128 |
| NCT01479881Hepatitis C · Belgium | 1 | Completed | Johnson & Johnson | Dec 2011 | 29 |
| NCT01438710Renal Insufficiency · United States | 3 | Completed | Veloxis Pharmaceuticals | Aug 2012 | 44 |
| NCT01430065Pharmacokinetics of ASP015K · United States | 1 | Completed | Astellas Pharma | Jun 2009 | 24 |
| NCT01371344Heart Transplantation · Belgium, France, Germany and more | 4 | Terminated | Astellas Pharma | Apr 2, 2017 | 47 |
| NCT01371331Kidney Transplantation · Belgium, France, Germany and more | 4 | Completed | Astellas Pharma | Feb 3, 2015 | 52 |
| NCT01342016Lupus Nephritis · China | 3 | Terminated | Astellas Pharma | May 2013 | 84 |
| NCT01339468Liver Transplantation · Korea, Republic of | 4 | Completed | Astellas Pharma | May 27, 2014 | 100 |
| NCT01332201Heart Transplantation · Austria, Belgium, France and more | 2 | Completed | Astellas Pharma | Nov 2013 | 17 |
| NCT01325571Myasthenia Gravis · China | 3 | Completed | Astellas Pharma | May 2014 | 83 |
How it is read
Names in the registry
- “Tacrolimus”, 50 entries
- “tacrolimus”, 26 entries
- “Advagraf”, 12 entries
- “tacrolimus ointment”, 9 entries
- “Prograf”, 7 entries
Codes read as this program: LP10, FK506E, FK506MR.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 19 studies
- Renal Insufficiency, 11 studies
- Arthritis, Rheumatoid, 7 studies
- Graft vs Host Disease, 5 studies
- Lupus Nephritis, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.